-

Tempus Accelerates Its EHR Integration Scope With Epic

Tempus expands its existing provider EHR integrations to offer physicians seamless access to its genomic testing

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, announced that it is working with Epic to offer providers in-workflow integrations at scale. Since its founding, Tempus has strived to provide physicians seamless access to next-generation sequencing and the accompanying data to support them in providing personalized patient care.

Through Epic’s Genomics module, Tempus has been paving the way with live EHR integrations that embed test ordering and discrete genomic data delivery into the existing clinical workflow, with 8 institutions already live and a number underway. Tempus’ initial work with Epic made it the first somatic sequencing lab in the country creating these types of integrations.

“Tempus understands our need for efficient, streamlined ordering and reliable discrete results all in one place so that we can promptly implement the actionable results for our patients,” said Karen Huelsman, MS, LGC, Precision Oncology Lead at TriHealth Precision Oncology. “More than that, Tempus continually works with our precision oncology team to optimize the integration and apply Epic’s Genomics module components to fit our specific, changing needs.”

Tempus is building on that existing work to accelerate and scale this endeavor. In 2022, Epic and Tempus expect to support large-panel genomic sequencing testing across the Epic network. This new capability is designed to reduce integration timelines from months to weeks and make it significantly easier for health systems to enable Tempus testing options within their Epic EHR.

"We realized that we could significantly reduce the amount of time physicians spend ordering Tempus' smart diagnostics and viewing results at the point of care, ultimately freeing up more time for them to spend with their patients,” said Terron Bruner, Chief Commercial Officer of Tempus. “Epic introduced the technology we needed to make these kinds of integrations not only possible, but also seamless for providers, like TriHealth, seeking these solutions.”

“Our work with Tempus presents a tremendous opportunity to advance precision medicine by empowering providers and patients with insights from integrated genomic data,” said Alan Hutchison, Vice President of Population Health at Epic. “Together we can deliver on the promise of precision medicine and positively impact early detection, treatment, and survival.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Hanah Heintzelman
hanah.heintzelman@tempus.com

Tempus


Release Versions

Contacts

Hanah Heintzelman
hanah.heintzelman@tempus.com

More News From Tempus

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus’ growing cardiovascular portfolio, expanding the company’s suite of next-generation AI products aimed at ide...

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, can perform clinically important diagnostic tasks using simple prompts and can be leveraged for a variety of downstream applications. The results were published in Nature Medici...

Tempus Reports Second Quarter 2026 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. “Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostic...
Back to Newsroom